Abstract:
:Gastrointestinal endoscopy and endoscopic ultrasound not only provide strategies to diagnose and stage malignancy, but also to administer palliative and definitive care. Options for anticancer therapy include endoscopic mucosal resection, photodynamic therapy, thermal therapy, self-expanding metal stents and recently, endoscopic ultrasound-guided therapy, such as intratumoral injection. This review summarizes the available endoscopic techniques with a discussion of indications and recent clinical data pertaining to gastrointestinal malignancy. This review will inform the reader of emerging treatment options and stress the importance of incorporating gastroenterologists into the multidisciplinary approach in the management of gastrointestinal cancers.
journal_name
Expert Rev Anticancer Therjournal_title
Expert review of anticancer therapyauthors
Wong RF,Bhutani MSdoi
10.1586/14737140.5.4.705keywords:
subject
Has Abstractpub_date
2005-08-01 00:00:00pages
705-18issue
4eissn
1473-7140issn
1744-8328journal_volume
5pub_type
杂志文章,评审abstract:INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2019.1538797
更新日期:2019-01-01 00:00:00
abstract::A large number of different 5-hydroxytryptamine (HT)(3) receptor antagonists have been marketed with the indication of preventing nausea and vomiting induced by chemotherapy--palonosetron is the most recently developed of these. Pharmacologic studies have revealed that palonosetron has a long half-life, a high affinit...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.09.175
更新日期:2010-02-01 00:00:00
abstract::The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.7.1.57
更新日期:2007-01-01 00:00:00
abstract::Fludarabine is a prodrug that is converted to the free nucleoside 9-beta-D-arabinosyl-2-fluoroadenine (F-ara-A), which enters cells and accumulates mainly as the 5'-triphosphate, F-ara-ATP. F-ara-ATP has multiple mechanisms of action, which are mostly directed toward DNA. Collectively, these actions affect DNA synthes...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.6.9.1141
更新日期:2006-09-01 00:00:00
abstract:INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2018.1458613
更新日期:2018-06-01 00:00:00
abstract:BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1586/14737140.2015.1061937
更新日期:2015-01-01 00:00:00
abstract:INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2018.1480942
更新日期:2018-07-01 00:00:00
abstract::The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.12.99
更新日期:2012-09-01 00:00:00
abstract::Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.12.59
更新日期:2012-07-01 00:00:00
abstract::miRNAs, which are small single-stranded RNA molecules composed of 18-23 nts, act as oncogenes or tumor suppressor genes playing important roles in the processes of tumor formation, infiltration and metastasis. Lung cancer currently has the highest morbidity and mortality among all malignant tumors; yet, lack of early ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2013.870037
更新日期:2014-04-01 00:00:00
abstract::Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.3.1.55
更新日期:2003-02-01 00:00:00
abstract::The development of consensus classifications for renal epithelial neoplasia in 1996 and 1997 led to the recognition of renal adenoma, renal oncocytoma and metanephric adenoma/adenofibroma as benign tumors and conventional (clear cell) renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and collecting duct carci...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.1.4.576
更新日期:2001-12-01 00:00:00
abstract::Pegylated liposomal doxorubicin (PLD) was first approved for platinum-refractory ovarian cancer in 1999 and then received full approval for platinum-sensitive recurrent disease in 2005 by the US FDA. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Phase-II and III clini...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.11.187
更新日期:2012-01-01 00:00:00
abstract::Since its introduction almost 40 years ago, intravesical BCG for non-muscle invasive bladder cancer remains one of the most successful cancer immunotherapies. However, up to 40% of patients will progress after BCG therapy and develop invasive bladder cancer. Despite its extensive clinical use, we are only beginning to...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2015.1015419
更新日期:2015-05-01 00:00:00
abstract::It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.09.38
更新日期:2009-08-01 00:00:00
abstract::In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclo...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.12.177
更新日期:2013-02-01 00:00:00
abstract:INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2020.1770088
更新日期:2020-06-01 00:00:00
abstract::The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.4.5.865
更新日期:2004-10-01 00:00:00
abstract::Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live long enough to experience disease progression despite castration. This scenario is defined as castration-resistant prostate cancer (CRPC) and has a poor outcome and...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2013.811154
更新日期:2013-07-01 00:00:00
abstract::Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2014.848065
更新日期:2014-01-01 00:00:00
abstract::Ca(2+) influx at critical points in the cell cycle is required for proliferation. This requirement is so ubiquitous that its occurrence is often treated as background noise. Yet without it, cells stop dividing, suggesting an obvious and potentially effective way to treat cancer. To control proliferation by controlling...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.13.34
更新日期:2013-05-01 00:00:00
abstract::Protein kinase (PK)Calpha and epsilon are rational targets for cancer therapy. However, targeted experimental therapeutics that inhibit PKCalpha or epsilon are unavailable. The authors established recently that covalent modification of an active-site cysteine in human PKCepsilon, Cys452, by small molecules, for exampl...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.6.2.175
更新日期:2006-02-01 00:00:00
abstract::Neurocognitive function (NCF) impairment is an important component of primary and metastatic brain tumors and their therapeutic interventions. As a result, modern clinical trials of cranial irradiation for adult cancer patients have incorporated NCF testing as a primary or secondary end point. In doing so, these clini...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.12.34
更新日期:2012-05-01 00:00:00
abstract::Soft tissue sarcomas are a diverse group of rare tumors that comprise 1% of all cancers. Few randomized trials of chemotherapy have been performed but there is a clear role for agents such as doxorubicin and ifosfamide in the palliation of advanced disease. There is uncertainty as to whether sequential single-agent tr...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.09.176
更新日期:2010-02-01 00:00:00
abstract::According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.11.206
更新日期:2012-02-01 00:00:00
abstract::Until recently, cytokine therapy has been the only validated option for patients with advanced renal cancer. IFN-alpha is one of very few treatments that have demonstrated improved median survival compared with the appropriate control. In patients with synchronous metastases at diagnosis, debulking nephrectomy prior t...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.8.6.907
更新日期:2008-06-01 00:00:00
abstract::Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.6.7.1087
更新日期:2006-07-01 00:00:00
abstract::Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.3.2.203
更新日期:2003-04-01 00:00:00
abstract:INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2018.1528146
更新日期:2018-12-01 00:00:00
abstract::Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.10.216
更新日期:2011-05-01 00:00:00